Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 311 | 52 | 253 |
| Samples | 190 | 32 | 154 |
| Peptides | 156 | 26 | 134 |
Function
RPL5 · Ribosomal protein L5
Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of four RNA species and approximately 80 structurally distinct proteins. This gene encodes a member of the L18P family of ribosomal proteins and component of the 60S subunit. The encoded protein binds 5S rRNA to form a stable complex called the 5S ribonucleoprotein particle (RNP), which is necessary for the transport of nonribosome-associated cytoplasmic 5S rRNA to the nucleolus for assembly into ribosomes. The encoded protein may also function to inhibit tumorigenesis through the activation of downstream tumor suppressors and the downregulation of oncoprotein expression. Mutations in this gene have been identified in patients with Diamond-Blackfan Anemia (DBA). This gene is co-transcribed with the small nucleolar RNA gene U21, which is located in its fifth intron. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed throughout the genome. [provided by RefSeq, Mar 2017].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000370321 | P46777 | 202 | 140 |
| ENST00000645119 | A0A2R8Y4A2* | 107 | 74 |
| ENST00000645300 | A0A2R8Y6J3* | 2 | 2 |
Gene Properties
Recurrent Mutations
All 140 amino-acid changes on canonical ENST00000370321 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RPL5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RPL5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 16/612 3% |
| Melanoma | 2/210 1% | 26/1899 1% |
| Ewings Sarcoma | 2/63 3% | 2/262 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Colorectal Carcinoma | 7/143 5% | 19/3239 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 4/810 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 7/1390 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 2/94 2% | 6/1515 0% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Glioma | 0/52 0% | 10/2127 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Head and Neck Carcinoma | 3/85 4% | 3/1574 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 7/2640 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Neuroblastoma | 0/87 0% | 2/1331 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 3/2550 0% |
Mutation Distribution
Where RPL5 is mutated · all tissues, split by cell line vs tissue
How many mutations in RPL5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 311 mutations in RPL5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|